Tiny study reveals how liver cirrhosis alters drug breakdown
NCT ID NCT05741385
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study looked at how people with and without liver cirrhosis process five common medicines: caffeine, warfarin, omeprazole, metoprolol, and midazolam. Only 4 participants took part, including healthy volunteers and those with mild or moderate cirrhosis. Researchers took frequent blood samples to measure drug levels, aiming to understand how liver damage affects drug metabolism. The results may guide future drug development for people with liver disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
caffeine, warfarin, omeprazole, metoprolol, and midazolam
What this could lead to
If successful, this study could help researchers design better dosing guidelines for new medicines in people with liver cirrhosis.
What could go wrong
This is a very small, early-stage profiling study with only 4 participants. Results may not apply to all patients, and the medicines tested are already approved, so no new treatment is being developed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany